UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August, 2016

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street Park Rehovot P.O.B 2100 Rehovot 7612002 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⊠ Form 40-F □
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Presentation to Accompany Evogene's Second Quarter 2016 Financial Results Conference Call.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: August 11, 2016

By: <u>/s/ Eyal Leibovitz</u> Eyal Leibovitz Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

99.1 Presentation to Accompany Evogene's Second Quarter 2016 Financial Results Conference Call.





Safe Harbor Statement



This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Introducing Evogene




- Located
 - HQ Rehovot, Israel
 - R&D site St. Louis, USA
- ~200 employees, 80% R&D
- Listed TASE (2007); NYSE (2013)
- Innovative discovery technology broadly applicable proprietary platform, combining cutting-edge computational capabilities with interdisciplinary biological expertise
- Two R&D hubs for improving crop productivity
 - · Crop enhancement yield, drought tolerance and fertilizer use efficiency
 - · Crop protection insect resistance, disease and weeds
- Collaborations with world-leading agriculture companies - Bayer, BASF, DuPont, Monsanto, Syngenta
- Targeting 3 major markets
 - Seed traits ~\$37B¹
 - Ag-Chemicals ~\$55B²
 - Ag-Biologicals ~\$4B³



Source: Phillips McDougall , 2016
 Source: Phillips McDougall , 2015


³ Source: Research & Markets, 2016





Market overview & potential





^{*} Source: Phillips McDougall

^{**} Source: Internal analysis





✓ Plant genes demonstrated potential to achieve yield enhancement in corn and soybean

Subset of genes improved predicted trait attributes for yield -





Further testing undertaken for these genes as well as additional previously discovered genes

Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology

February 23rd, 2016

Results, obtained for a set of Evogene discovered genes, in testing by its key collaborator, Monsanto, demonstrate potential to achieve yield enhancement in corn and soybean.

Rehovot, Israel - February 23rd, 2016 - Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries announced today positive results from the testing of a set of the Company's discovered genes in corn and soybeans conducted this past season by its key collaborator, Monsanto. These are the first results for genes discovered and tested pursuant to a 'Trait-First' methodology implemented in the frame of the parties' on-going, multi-year collaboration which focuses on yield enhancement and abiotic stress resistance.

Insect Control - recent results & updates



✓ Microbial genes demonstrated activity against target insects

Examples for positive microbial genes - demonstrated positive results in insect feeding assay

Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration

May 16th, 2016


Novel proteins for activity against target insects being advanced to plant validation

Rehovot, Israel and Davis, California – May 16, 2016 – Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, and Marrone Bio Innovations Inc. (MBI), (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, announced today that they have successfully met an important milestone in their multi-year collaboration focused on discovery and validation of novel genes for insect control. In diet-based insect assays, certain proteins demonstrated control activity against several target pest insects, including fall armyworm, a devastating pest that causes annual damage of approximately \$1 billion worldwide. Based on these results, selected bioactive proteins are now being advanced by the two companies to plant validation.

EVO50010076 - Fall Army Worm

EVO50010076


No treatment



EVO50010061 - Soybean Looper


EVO5001061

No treatment












<u>Example for active gene –</u> activity in Banana against Black Sigatoka disease



- Eight events were evaluated, statistically significant
- Magnitude of results repeated in two generation

Undergoing larger scale field trial in Central America

*BSI - 100 X (youngest leaf spotted -1)
Number of standing leaves


Promoters-recent results & updates



✓ Promoters* with initial validation for specific expression patterns

<u>Examples for successful promoter predictions</u> – initial positive results in model plant validation





^{*}Segments of DNA that determine expression patterns for genes. Such promoters when used with appropriate genes are an essential component of improving seed trait efficacy.

Innovative Ag-Chemicals






Innovative Ag-Chemicals

Market overview & potential





Innovative Ag-Chemicals

Herbicides - recent results & updates



✓ Herbicide Targets validated in plant system

<u>Example for Herbicide Target -</u> induced inhibition of targets leads to plant death

Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides

July 29th, 2015


- Newly discovered targets predicted to represent new modes of action

Rehovot, Israel – July 29, 2015 – Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today the discovery and successful validation in plants of the first set of novel plant targets, representing a key milestone in its product program for new chemical herbicides. Targets for herbicides are vital plant macro-molecules taking part in essential biological processes in weeds ('modes of action'). The Evogene discovered targets will now be the subject of a unique methodology for the discovery of chemical molecules that can inhibit their functionality, resulting in weed death. These chemical molecules would then serve as the basis for the development of the active

Normal target activity - healthy plant








Target inhibition - dying plant








✓ Compounds displaying herbicide activity against weeds

<u>Example for Compound -</u> displaying herbicidal activity In greenhouse

> Panel of weeds – 15 days post application

EVO AG1345*



Commercial herbicide (positive control)




No treatment (negative control)



*Prior to optimization

Novel Ag-Biologicals






Novel Ag-Biologicals

Market overview & potential









*Data based on Research and Markets, 2016

Harnessing the power of Microbiome

Human microbiome understanding leveraged into plant



Enabled by availability of new and affordable genomic data



Major ag companies taking significant steps to enter this market











Novel Ag-Biologicals

Biostimulants - recent results & updates



